Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. - Wikidata - awgldk - TriplyDB

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

http://www.wikidata.org/entity/Q37659113

about

Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia T cell receptor mimic antibodies for cancer therapy Immunotherapy of Childhood Sarcomas Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Adoptive T-cell therapy for Leukemia Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Current issues in malignant pleural mesothelioma evaluation and management Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.Strategies to genetically engineer T cells for cancer immunotherapy.A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.Chimeric antigen receptor T cell therapy in AML: How close are we?Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis.Hypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Inducible T-cell receptor expression in precursor T cells for leukemia control.Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo Approaching untargetable tumor-associated antigens with antibodies.Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.CAR T cells for acute myeloid leukemia: the LeY of the land.Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Antibody therapy for acute myeloid leukaemia.Adoptive immunotherapy for cancer.Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.Canonical and new generation anticancer drugs also target energy metabolism.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.Opportunities and challenges for TCR mimic antibodies in cancer therapy Engineered T cells: the promise and challenges of cancer immunotherapy.Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants.Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.

P2860

Q26744111-458CB55F-CE46-4278-BB4A-26259EA77034 Q26768271-1252E3BA-6B73-45A3-AB2C-CD45F61F1E0C Q26795369-B80C35A6-AD4D-4274-9993-4CD42F9692D5 Q26853171-8DACF183-DC91-4A86-A966-A41BEE11D096 Q27006934-AF43951B-3E5D-4F05-B73F-15169424377F Q27313856-21464990-B548-4563-B8B3-9A19CE5820A8 Q28393560-30081FF4-80F1-48EA-A85E-943669FD3B5A Q30382749-D67883D7-95CF-4F21-AB2E-C63853893049 Q33655849-4D5688E9-37D6-4441-80CA-9E4882BADCAC Q33714727-28680AD7-A49C-42B9-A566-9FF928CED606 Q33992114-623CA049-DF55-40E5-9439-2C387DD6DB97 Q34545962-12FAFD78-06EA-4A6E-B53D-7500DC20417F Q35000449-FEF9CCC3-25E8-487A-A13C-B67872AF06E3 Q35157134-23F24C55-2C2E-41B3-B417-9F976AAC5278 Q35203507-0BFC6E4C-1485-48F7-B8B8-6A41AC4D53C4 Q35626579-9CA7CB5C-BDAF-4C2E-9E22-77CC80295EA9 Q35634680-B7C42EE2-8C3A-4036-BCF1-71A5C5516B85 Q36166038-41F8D584-AEF8-4C9A-9D9F-7B15869EFE54 Q37072087-CC1F04C9-1DE9-4520-87A1-99A7754367B0 Q37194869-BC340F1C-77C7-483C-AB68-688BC9102C3E Q37236903-299368E5-EAE6-4D54-A0D8-E61480D23FB5 Q37257207-3C598123-4695-432B-8CCC-67B52C1B502A Q37316892-4B4D73C5-2FD3-4EEA-A21E-721F5A5302BF Q37319382-16E7B7CC-3579-44BF-859B-82E5C2A947E5 Q37384745-863D0E9D-8CE9-4488-AE3F-0BE44BC59525 Q37587956-A57EEB0C-BD86-49AD-9E99-CDC8E29658BF Q38169814-186B6D09-200F-4073-9D5F-FE4499670F53 Q38170496-25D90031-B93E-44A3-A0AA-D539454C9734 Q38170501-44367E5A-F693-48D0-B2FA-110E44C78261 Q38208982-E89274F4-3C67-4E3B-8644-6193F28473E4 Q38289029-12D8E3C4-960B-43CF-9276-4B10B448020B Q38700209-2CDFF959-6658-4D76-AF56-AAC0DDE56DC8 Q38719407-0854FD99-D493-479E-9C62-BBBB34759DC0 Q38739446-9BAC036F-FC27-4E22-84A0-D524F19AB361 Q38812269-DB0AED5B-8C10-4D68-9520-DA82AEAD7EBF Q38828829-A0B98E4F-D4DA-4F89-B671-C659883A4F34 Q39085019-420928E4-B791-4191-A033-3655FE9068BF Q40064164-1961C5F6-9478-46A8-9611-D5B9460D9DD8 Q40973052-10CAE1A5-4CF8-4CB6-9C19-2C925633A3DF Q41298278-5558F0FC-0523-42BD-BBD6-334893C68FCF

P2860

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

http://www.wikidata.org/entity/Q37659113

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

@en

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

@nl

type

label

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

@en

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

@nl

prefLabel

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

@en

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

@nl

P1433

Q37659113-2A803ECB-C184-4A09-8129-07C4D2A5A5D3

P1476

Q37659113-3BA351DA-9830-48AE-B161-FA4968F07DD4

P2093

Q37659113-2B658366-6039-4B77-88CE-41209DB2573B

Q37659113-5ACA62E8-82C3-4B19-B662-58E51DA13273

Q37659113-5E37BF30-5564-45B3-8BAD-192D65D88870

Q37659113-641BCFE9-85C0-4CDB-9F55-68035D59E543

Q37659113-71FEBAA9-4E24-4342-A012-E7A9A15A7FE7

Q37659113-735C6561-C46B-4AAB-B1D0-1A23D6AED2E7

Q37659113-7F9B0745-F664-4195-87D9-BCCED550248F

Q37659113-817C72C2-43BF-4CFC-B1F1-90FE74C36C5B

Q37659113-9AB11027-9A2E-4F45-83C7-7E9F7909A75C

Q37659113-B09679C4-F88A-4B54-93F1-9828EB0018DE

P2860

Q37659113-011D8AD4-EECE-4C66-88A3-94438A5C7C13

Q37659113-19624F22-400B-4605-9261-55F1281B6D4C

Q37659113-1B57526C-97AD-4039-9632-6BA828ED8B32

Q37659113-1E78AE4C-E30D-4DEE-9F35-9E2707AE0B7A

Q37659113-250DEA3F-C298-4509-9FCB-7E04235846AB

Q37659113-2939BB2F-B2F2-4612-841D-1C674FEE2C50

Q37659113-29D6D3AB-7BA6-484B-B4DF-A3018844D73E

Q37659113-2FE54399-6B23-425E-80EC-74CB986A784C

Q37659113-347B7988-F248-452C-96CA-859A5D8F5A18

Q37659113-36217FCD-8065-4AFC-B16D-CF2412D09B18

P304

Q37659113-9899E128-7B58-4BC2-8732-A9E01097C63D

P31

Q37659113-724832BF-91EF-4157-A08E-F8900A276D83

P356

Q37659113-E89CACEA-8FB5-42C3-81F7-56A79C53FE8D

P407

Q37659113-F0080886-2556-4299-960F-53B806824C99

P433

Q37659113-A4BE5340-B3D9-48DB-922E-2EE5E43821D6

P478

Q37659113-8B1E1956-C588-458F-A79B-B83E33C98421

P50

Q37659113-6BD6E54D-B2DC-4577-92CF-FE0997DF696F

Q37659113-7756825B-84D3-457B-A253-A6B3F388A429

P577

Q37659113-2BC261AB-9963-4AC3-97E7-F3106E1C6970

P698

Q37659113-3F916D98-B55A-457E-B535-CF52BE4950FB

P921

Q37659113-6C3D918F-3F22-426D-ACB4-FE2449839B0A

P932

Q37659113-F009D418-283D-4B7A-AE81-18C9E520F6F6

P356

SCITRANSLMED.3005661

P1433

Science Translational Medicine

P1476

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody

@en

P2093

Cheng Liu

http://www.w3.org/2001/XMLSchema#string

David A Scheinberg

http://www.w3.org/2001/XMLSchema#string

Dmitry Pankov

http://www.w3.org/2001/XMLSchema#string

Ekaterina Doubrovina

http://www.w3.org/2001/XMLSchema#string

Emily Casey

http://www.w3.org/2001/XMLSchema#string

Hong Liu

http://www.w3.org/2001/XMLSchema#string

Joseph Whitten

http://www.w3.org/2001/XMLSchema#string

Liang Zhou

http://www.w3.org/2001/XMLSchema#string

Michael Curcio

http://www.w3.org/2001/XMLSchema#string

Nicholas Veomett

http://www.w3.org/2001/XMLSchema#string

P2860

Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues

Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials

Antibody therapy of cancer

Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Production of human monoclonal antibodies against Fc(epsilon)RI(alpha) by a method combining in vitro immunization with phage display.

Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

P304

176ra33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3005661

http://www.w3.org/2001/XMLSchema#string

P407

P433

176

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23486779

http://www.w3.org/2001/XMLSchema#string

P921

P932

3963696

http://www.w3.org/2001/XMLSchema#string